Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Thyroid Disorders
Given the newer ATA guidelines, what is your approach to the management of Hurthle cell carcinoma?
Related Questions
How do you determine when to treat versus monitor subclinical thyroid disease early in pregnancy in patients with a negative TPOAb?
Can carbamazepine make thyroid function test results look spuriously abnormal?
What is the optimal frequency for follow-up of low-risk sub-centimeter thyroid cysts?
Do you avoid the use of beta blockers when treating hyperthyroidism in patients with well controlled asthma or COPD?
Are you more likely to recommend medical management for obesity instead of bariatric surgery in patients with preexisting hypothyroidism, given a recent study showing increased risks of complications?
How do you approach the use of supraphysiologic T4 doses in patients with intermediate- and high-risk differentiated thyroid cancer, considering that elevated FT4 levels have not been linked to progression-free survival in recent clinical data?
What factors do you consider when deciding between RFA and surgery for a patient with a benign thyroid nodule causing dysphagia?
In middle-aged adults with TSH 5–10 mIU/L and no symptoms, would you start levothyroxine or monitor, and does your threshold change with cardiovascular risk factors?
How do you counsel breastfeeding women on their limitations post radioactive iodine ablation for thyroid cancer treatment?
Is there a role for adding methotrexate to methimazole in the treatment of Graves' disease?
